Endocrine Abstracts

Introduction: The prolactinoma is the most common functioning pituitary tumour. There are few long-term studies on the optimal duration of treatment with dopamine agonists prolactinoma to ensure healing without recurrence after stopping the medication and do not provide a consensus on it or on withdrawal criteria treatment.Objectives: To establish the prevalence of withdrawal of treatment macroprolactinomas and evaluate criteria prolactinoma cure medical...

Object: Nonfunctioning pituitary adenomas can experiment recurrence and/or progression (R/P) several years after surgery in about 15–50% of patients. There is few evidence about risk factors that could predict R/P. The aim of this study is to identify them and describe our experience through a long term of follow-up in pituitary macroadenomas.Methods: Retrospective cohort analysis of 64 patients who underwent surgery between 1990 and 2013. The main ...

Introduction: The role of mitotane as an adjuvant therapy for adrenocortical carcinoma (ACC) remains a contentious topic due to the scarcity of robust randomized clinical trials, attributed to the low incidence of this neoplasm. Despite this, the prognosis following surgery for localized tumors is generally poor, leading to varied clinical practices.Methods: This study utilized patient data from the ICARO registry of the GETHY group and SEEN, with diseas...